Primary graft dysfunction (PGD) following lung transplantation is associated with elevated recipient plasma levels of plasminogen activator inhibitor-1 (PAI-1) and the receptor for advanced glycation end products (RAGE). However, the significance of these biomarkers in the donor plasma is uncertain. We hypothesized that elevated donor plasma levels of PAI-1 and RAGE would be associated with recipient PGD. We carried out a prospective unmatched case-control study of double-lung transplant recipients between May 2014 and September 2015. We compared donor plasma levels of PAI-1 and RAGE using rank-sum tests and t tests, in 12 recipients who developed PGD grade 2 or 3 within 72 hours postoperatively with 13 recipients who did not.
| INTRODUCTION
Severe primary graft dysfunction (PGD) is the main cause of early morbidity and mortality following lung transplantation, affecting approximately 15%-30% of recipients post-transplantation. 1 Early prediction of PGD could allow earlier interventions and better recipient outcomes. The ability to identify donor lungs at risk for PGD prior to recipient selection would affect recipient outcomes and is the earliest possible time-point for intervention. Multiple characteristics of the donor, such as cigarette smoke exposure and increased age, increase the risk of PGD. 1, 2 Other factors, as measured by biomarker levels, may also contribute to PGD risk. For example, plasminogen activation inhibitor 1 (PAI-1) mediates the imbalance of fibrin deposition and degradation in the lung and has been associated with lung injury. 3 Another, the receptor for advanced glycation end products (RAGE), is a known marker for alveolar epithelial injury. 4 It is therefore not surprising that elevated plasma levels of PAI-1 and RAGE in the recipient are known to be associated with a higher risk of developing PGD. 5, 6 Elevated concentrations of different biomarkers in the donor, such as IL-8, endothelin-1, and RAGE, have also been associated with development of PGD in the recipient. [7] [8] [9] However, measurements in these studies were conducted on donor bronchoalveolar lavage (BAL) fluid or tissue biopsies from donor lungs.
ments. Given that the pilot nature of this study and our small numbers limited our ability to adjust for potential confounders, these exclusion criteria were chosen in an attempt to obtain a small yet relatively similar recipient population. Inclusion criteria for the study were as follows: having undergone a bilateral lung transplant during the study period and having available donor plasma samples. All controls had no evidence of PGD grade 2 or 3 at any time-point within 72 hours postoperatively. All cases had persistent PGD grade 2 or 3 at ≥2 timepoints within 72 hours postoperatively. To account for potential variations in associated biomarker levels given severity of PGD grade, further sensitivity analyses were also conducted by limiting cases to only those recipients who developed PGD grade 3. For these sensitivity analyses, cases with persistent PGD were further narrowed to those recipients who developed PGD grade 3 at any time-point, as opposed to those who developed persistent PGD grade 2 only, as well as those who developed persistent PGD grade 3 at ≥2 time-points.
| Definition of primary graft dysfunction
As defined by ISHLT criteria, 10 development of PGD was determined by the recipient PaO 2 /FiO 2 ratio and chest radiograph review. Timepoints for PGD grading were at T0, T24, T48, and T72. PaO 2 :FiO 2 ratio was obtained from the electronic medical record. Chest radiographs were reviewed to determine the presence or absence of infiltrates.
Any recipient receiving postoperative extracorporeal oxygenation (n = 3) was graded as PGD grade 3. 
| Data collection and management

| Measurement of plasma biomarkers
Donor blood was collected immediately before organ recovery, refrigerated, and centrifuged within 12 hours or less. Plasma was then collected and stored at −80°C until immediately before the assay was performed. Plasma levels of biomarkers were measured in duplicate using enzyme-linked immunosorbent assay kits (ELISA) for RAGE (RAGE ELISA; R&D, Minneapolis, MN, USA) and PAI-1 (PAI-1 ELISA; R&D).
| Statistical analysis
Continuous, normally distributed variables were compared between cases and controls using 2-tailed t tests. Continuous nonnormally distributed variables are expressed as median values and interquartile range (IQR) and compared using Wilcoxon's rank-sum test. Biomarker levels were not normally distributed and were therefore analyzed using Wilcoxon's rank-sum test. Biomarker levels were also log-transformed to apply t tests. Because the natural log of zero is an undefined number, any plasma sample with an undetectable level of a biomarker was recorded as ½ of the minimum detectable dose of the assay to allow for log-transformation.
Categorical variables were compared using chi-square or Fisher's exact tests. Correlation between continuous variables was analyzed using Spearman's rank test because of nonlinear relationships between continuous predictors and continuous biomarker levels.
Because of small sample size, we decided to forgo logistic regression with adjustment. A P-value of <.05 was considered significant.
Power calculations performed using a total cohort of 25 recipients, 
| Ethics approval and consent to participate
| RESULTS
| Recipient selection
Of 
| Baseline characteristics of donors and recipients
Cases were more likely than controls to have a donor older than age 45 (P = .039). Cases also had a higher recipient BMI than controls (P = .001; Table 1 ). In addition, recipient survival to 30 days was 100%.
| Donor biomarker levels
Donor plasma levels of PAI-1 were higher in cases compared with controls in both the raw (median 2.7 ng/mL [IQR: 2.1, 5.5] vs 1.4
[IQR: 1.1, 2.9]; P = .03) and log-transformed analyses (ln mean ± SD 1.1 ± 0.2 ng/mL vs 0.2 ± 1.3; P = .03). A trend was observed toward higher plasma RAGE levels in donors whose recipients later developed 
| DISCUSSION
In this study, we found higher donor plasma levels of PAI-1 and a trend toward higher donor plasma levels of RAGE in lung transplant recipients who later developed severe PGD compared with those who did not. These findings provide suggestive early evidence that donor abnormalities in coagulation and fibrinolysis may contribute to the risk of developing PGD in lung transplant recipients.
Our findings are consistent with other work investigating the association of postoperative levels of PAI-1 in the recipient with PGD following lung transplantation. In 1 prospective cohort study of lung transplant recipients, PAI-1 and protein C were measured preoperatively in lung transplant recipients and at 6, 24, 48, and 72 hours after allograft reperfusion. 6 Plasma levels of PAI-1 at 6, 24, and 48 hours postreperfusion were higher in recipients who developed PGD than in those who did not. PAI-1 levels were not different between groups at either the preoperative or 72 hour postoperative time-points.
Preoperative protein C levels did not differ between recipients with PGD and those without PGD, but were lower at each postoperative time-point in recipients with PGD. Thus, low protein C and elevated PAI-1 plasma levels in the early postoperative period were associated progress from acute to sustained cellular dysfunction. 11 BAL levels of RAGE are associated with increased ischemic time and impaired alveolar fluid clearance. 12 Furthermore, elevated postoperative plasma levels of RAGE have been found to be associated with recipient development of PGD, duration of mechanical ventilation, and ICU length of stay. [13] [14] [15] Similarly, elevated levels of RAGE in donor BAL have also been associated with recipient development of PGD. 7 These findings lend further support to our observed trend and suggest that donor RAGE expression and type 1 alveolar epithelial cell injury play a role in recipient development of PGD.
Our study does have some limitations. Given its intent as a pilot study, we made the decision a priori to include only 25 recipients in the study. However, our small sample size limited our power to detect differences, although we were able to overcome this to some extent by log-transforming our data and using the t test. One consequence of our small numbers was our decision to define cases as recipient PGD grades 2 or 3 as opposed to grade 3 alone, as has been done in other work. 7 In addition, we limited our cases to double-lung transplant recipients and to only those recipients with PGD at >1 time-point in an attempt to select the most severe cases. While our selection of 12
cases from the 20 that met these criteria was random, we are unable to completely exclude the possibility that bias was introduced during this process. Therefore, we believe our results should be interpreted in the context of a pilot and exploratory study. Further work with larger numbers would be necessary to confirm our results. While we could not control for known donor and recipient risk factors, the differences we did identify were consistent with what has been previously published. In our study, cases were more likely to have a donor >45 years of age. This is consistent with prior work associating donor age of <21 and >45 years with recipient development of PGD. 2 Recipient weight and obesity are established risk factors for development of PGD, 1 as well as for increased mortality. 16 Consistent with this research, we also found that cases had a higher BMI than controls. The demographics of the recipients in our study therefore support the possible association between an overweight recipient and the development of PGD.
Whether specific combinations of donor characteristics contribute to disorders of coagulation in the donor, as seen by elevated levels of PAI-1, and thereby predisposing overweight recipients to PGD, is unclear. However, further investigation into these potential associations or pathways could be helpful in determining the pathophysiology of donor age or recipient BMI and an association with PGD.
Although our study has limitations, it features notable strengths, specifically, our focus on donor plasma. While numerous studies have shown that elevated concentrations of different biomarkers in the donor are associated with development of PGD in the recipient, 7-9,17-21 these studies focused on donor BAL fluid or donor lung tissue. Thus far, the only study that focused on donor blood examined the association between endothelin-1 levels in donor serum and development of PGD in F I G U R E 2 Biomarker levels in donor plasma compared between the 2 groups. PAI-1, plasminogen activator inhibitor-1; RAGE, receptor for advanced glycation end product; Log, natural logarithm recipients, but did not find a relationship. 9 Indeed, further investigation through measurements of PAI-1 levels in donor BAL as well as blood could provide an interesting confirmation of our results as well as examine the correlation and differences between the 2 compartments. Both BAL and lung tissue are challenging and expensive to sample, requiring sufficient time, and specialized training for both collection and processing. Donor blood represents a compartment that can be easily sampled at bedside with minimal training. Unlike both BAL and tissue, the simple nature of blood collection could allow donor sampling to occur at a vast variety of time-points prior to organ procurement. This could allow early donor lung stratification.
The ability to identify donor lungs at risk for PGD before recipient selection, the earliest time-point for intervention and risk stratification, has the potential to significantly affect recipient outcomes.
This pilot study has demonstrated the potential importance of the biomarker environment in the donor with short-term outcomes in the recipient. Future research is needed to take full advantage of this potential. Risk prediction models constructed using commonly available clinical variables of the recipient have already been developed. 22 In cohorts where prediction using clinical variables alone has failed, other variables such as extravascular lung water and protein biomarkers have been more successful. 15 Other studies have shown that combining biologic and clinical characteristics are more predictive than either biomarkers or clinical characteristics alone. 23 However, rapid sample assessment is necessary to realize the full potential of biologic markers. Recent work has demonstrated the possibilities of rapid biomarker analysis using fractal circuits, glass microchips, and gold microelectrodes, resulting in sample-to-answer times of 20-30 minutes. 24, 25 Rapid biomarker assessment of both the donor and the recipient could allow for precise donor risk stratification and recipient matching, resulting in superior outcomes. Furthermore, better risk prediction could also identify subjects at risk for PGD for enrollment in future clinical intervention trials.
| CONCLUSIONS
Elevated donor plasma levels of PAI-1 and a trend toward elevated levels of RAGE found in this nested case-control study provide evidence for a contribution from the donor to the risk of PGD development in recipients of lung transplantation. This finding is consistent with prior work on the importance of inflammation and coagulation factors in the pathogenesis of lung injury.
Further work uniting donor biologic and clinical markers into a simple risk assessment tool, in combination with evolving methods of rapid biomarker assessment, could provide a framework for improved donor risk stratification resulting in better recipient outcomes.
AVAILABILITY OF DATA AND MATERIALS
